On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

Ph.D., President and Chief Executive Officer of Aileron. "Additionally, we saw dose dependent effects in five biomarkers ...

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Renaissance Technologies LLC trimmed its position in Aileron Therapeutics, Inc. (NASDAQ:ALRN – Free Report) by 44.8% during the second quarter, according to its most recent 13F filing with the ...

Sadly, a follow-up never came. Enter the X4 Aileron, a competing “Designed for Xbox” grip that not only brings a pair of ...

AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Allarity Therapeutics (ALLR) has filed the following: We are offering 5,000,000 shares of our common stock at an assumed public offering price of $2.00 per share, the last reported... ByInvesting ...

AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to ...